Novogen's business is in the most pressing area facing medicine in the modern era - that of treating degenerative diseases.

• Cancer
• Heart disease (stroke, hypertension, coronary artery disease)
• Osteoporosis
• Chronic inflamatory diseases (rheumatoid arthritis, osteoarthritis, chronic back pain) 
• Inflammatory Bowel Disease (ulcerative colitis, Crohn's Disease)

While there are drugs available to treat these diseases, they either are poorly effective or only slow the rate of progression of the disease or are associated with unwanted side-effects.

Novogen is addressing this urgent area of medical need through the Novogen isoflavonoid technology platform - a platform that the Company believes offers the real prospect of not only treating, but also preventing, the onset of these common degenerative conditions.

To meet the challenge of an ambitious target of product development, the Company is structured into four divisions.

Pharmaceutical division – developing an extensive portfolio of prescription drugs

Marshall Edwards, Inc. – focused on the development of oncology (cancer) drugs

Consumer health division – developing a range of non-prescription products meeting important health needs of men and women